Abstract
The effects of two opiate agonists-antagonists, butorphanol (4.0 and 8.0 mg/kg) and buprenorphine (0.1 and 1.0 mg/kg), were assessed on locomotor activity and analgesia in DBA/2 and C57BL/6 mice. Diferrent behavioral effects were evident in these strains, which might becharacterized by different reactions to the effects of opiates and by differences in endorphin distributions and opiate receptor populations. In particular, buprenorphine acted as an agonist-antagonist to morphine in both strains while a dissociation of buturphanol effects was evident, depending on the strain considered. The clinical implications of these findings are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bruno F, Ferracuti F (1980) Preliminary report on a open clinical trial of butorphanol tartrate in the treatment of opiate addicts. II Lavoro Neuropsichiatrico 66:1–31
Cowan A, Lewis JW, Macfarlane IR (1977a) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537–545
Cowan A, Doxey JC, Harry EJR (1977b) The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 60:547–554
Houde RW (1979) Analgesic effectiveness of the narcotic agonist antagonists. Br J Clin Pharmacol (Suppl) 3:297–308
Jacob JJC, Michaud GM, Tremblay EC (1979) Mixed agonist-antagonist opiates and physical dependence. Br J Clin Pharmacol (Suppl) 3:291–297
Martin WR (1979) History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol (Suppl) 3:273–280
Mello NK, Mendelson JM (1980) Buprenorphine supresses heroin use by heroin addicts. Science 207:657–659
Oliverio A, Castellano C (1974) Genotype-dependent sensitivity and tolerance to morphine and heroin: Dissociation between opiateinduced running and analgesia in the mouse. Psychopharmacologia 39:13–22
Oliverio A, Castellano C, Racagni F, Spano PF, Trabucchi M, Cattabeni F (1978) Genetic aspects in narcotic action. In: Adler ML, Harrara L, samanin R (eds) Factors affecting the action of narcotics. Kaven, New York, pp 7–18
Pircio AW, Gylys JA, Cavanagh RL, Buyniski JP, Bierwagen ME (1976) The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic. Arch Int Pharmacodyn Ther 220:231–257
Rance MJ (1979) Animal and molecular pharmacology of mixed agonistantagonist analgesis drugs. Br J Clin Pharmacol (Suppl) 3:281–286
Reggiani A, Battaini F, Kobayashi H, Spano PF, Trabucchi M (1980) Genotype-dependent sensitivity to morphine: Role of different opiate receptor populations. Brain Res 189:289–294
Teitelbaum H, Giammatteo P, Mickley GA (1979) Differential effects of localized lesions of n. accumbens on morphine and amphetamine-induced locomotor hyperactivity in the C57BI/6J mouse. J Comp Physiol Psychol 93:745–751
Wikler A (1974) Requirements for extinction of relapse. Facilitating variables and for rehabilitation in a narcotic antagonist treatment program. In: Bravoe MC, Harris LS, May EL, Smith JP, Villareal JE (eds) Narcotic antagonists. Adv Biochem Psychopharmacol 8:399–414
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Filibeck, U., Castellano, C. & Oliverio, A. Differential effects of opiate agonists-antagonists on morphine-induced hyperexcitability and analgesia in mice. Psychopharmacology 73, 134–136 (1981). https://doi.org/10.1007/BF00429203
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00429203